Supplementary Table 1. Detailed Dose and Duration of Peginterferon and Ribavirin Therapy

Supplementary Table 1. Detailed Dose and Duration of Peginterferon and Ribavirin Therapy

Study / Detail
Andriulli, 2009 / Subjects who were rapid viral responders at week 4 received Peginterferon α-2a at a dose of 180 µg per week and Ribavirin at a dose of 1000-1200 mg for 12 weeks in one arm, and in the other arm discontinued Ribavirin at week 6, while remained on Peginterferon alpha-2a monotherapy for more 6 weeks.
Subjects who were HCV RNA positive at week4 received Peginterferon α-2a at a dose of 180 µg per week and RBV at a dose of 1000-1200 mg per day for 24 weeks.
Angelico, 2008 / Subjects received Peginterferon alpha-2a at a dose of 180 µg per week for the first 12 weeks, and after 12 weeks, subjects added ribavirin at a dose of 800 mg for 36 additional weeks.
Ascione, 2010 / Subjects affected by genotypes 1 and 4 received 48 weeks of treatment, while those affected by genotype 2 or 3 were treated for 24 weeks.
Benhamou, 2009 / Sujects affected by genotypes non-2/3 received 48 weeks of the treatment, while those affected by genotype 2 or 3 were treated 24 weeks.
Brady, 2010 / Subjects received Peginterferon alfa-2b 1.5 µg/kg once weekly and Ribavirin 13mg/kg per day for 48 weeks in one arm. Subjects in the other arm received Ribavirin 13mg/kg per day for 48 weeks and Peginterferon alfa-2b 3.0 µg/kg administered once weekly for 12 weeks followed by Peginterferon alfa-2b 1.5 µg/kg once weekly for 36 weeks.
Bruno, 2004 / Peginterferon alpha-2b was administered at a dose of 100 µg for weight 65kg or more and 80 µg for weight below 65kg, once weekly for the first 8 weeks, followed by a fixed dose of 50 µg once weekly for the next 40 weeks in combination with Ribavirin 1000-1200 mg per day for 48 weeks.
Diago, 2007 / Subjects received Ribavirin 1000-1200mg per day for 48 weeks plus in one arm Peginterferon alpha-2a 180 µg per week for 48 weeks, in another arm Peginterferon alpha-2a 270 µg per week, for the first 12 weeks and then 180µg per week for 36 weeks, and in another arm Peginterferon alpha-2a 360 µg per week, for the first 12 weeks and then 180 µg per week for 36 weeks.
Ferenci, 2010 / Subjects received Ribavirin 1000-1200mg per day for 72 weeks plus Peginterferon alpha-2a 180 µg per week, for the first 48 weeks and then 135µg per week for 24 weeks.
Gish, 2007 / Subjects affected by genotypes 1 and 4 received 48 weeks of treatment, while those affected by genotype 2 or 3 were treated for 24 weeks.
Ide, 2009 / In one arm the treatment was performed for 48 weeks, and in the other arm the treatment was performed for 44 weeks after patients became negative for HCV RNA (total duration, 48-68 weeks).
Jacobson, 2007 / 333 subjects affected by genotype 2 or 3 received 24 weeks of the treatment of Peginterferon alpha-2a 180 µg per week plus Ribavirin 800mg in one arm and 325 subjects affected by genotype 2 or 3 received 24 weeks of the treatment of Peginterferon alpha-2a 180 µg per week plus Ribavirin 800-1400mg in the other arm.
Jensen, 2009 / Subjects received Ribavirin 1000-1200mg per day for 48 weeks plus Peginterferon alpha-2a 180 µg per week for 48 weeks in one arm, and plus Peginterferon alpha-2a 360µg per week, for the first 12 weeks and then 180μg per week for 36 weeks. in another arm. Subjects received Ribavirin 1000-1200mg per day for 72 weeks plus Peginterferon alpha-2a 180 µg per week for 72 weeks in one arm, and plus Peginterferon alpha-2a 360 µg per week, for the first 12 weeks and then 180 µg per week for 60 weeks.
Kamal, 2007 / In the control group, subjects received Peginterferon alpha-2b 1.5 µg/kg per week plus Ribavirin 10.6mg/kg per day for 48 weeks.
In the study group, Subjects who were HCV RNA negative at week 4 received Peginterferon alpha-2b 1.5 µg/kg per week plus Ribavirin 10.6mg/kg per day for 24 weeks. Subjects who were HCV RNA negative at week 12 received the treatment for 36 weeks. Subjects who were HCV RNA positive at week 12 received the treatment for 48 weeks.
Langlet, 2009 / Subjects affected by genotypes 1, 4, 5 and 6 received 48 weeks of the treatment, while those affected by genotype 2 or 3 were treated 24 weeks.
Lodato, 2005 / In one arm, Peginterferon alpha-2b was administered twice a week. 1.5μg/kg on Monday + 1.0μg/kg on Friday, and Ribavirin 10.6mg/kg per day. Patients affected by genotypes 1 and 4 received 48 weeks of the treatment, while those affected by genotype 2 or 3 were treated for 24 weeks.
In the other arm, subjects who affected by genotypes 1 and 4 received Peginterferon alpha-2b 1.5 µg/kg per week plus Ribavirin 10.6mg/kg per day for 48 weeks while those who affected by genotype 2 or 3 were treated for 24 weeks.
Manns, 2001 / Subjects in one arm received Peginterferon alpha-2b, 1.5μg/kg per week for 4 weeks then 0.5μg/kg per week plus Ribavirin 1000-1200mg/day for 48 weeks. Subjects in the other arm received Peginterferon alpha-2b 1.5 µg/kg per week plus Ribavirin 800mg/day for 48 weeks
Marcellin, 2007 / Subjects (3 subjects) who were HCV RNA undetectable at week 24 continued on their assigned treatments for an additional 24 weeks. The others received the treatment for 24 weeks.
Marcellin, 2010 / Sujects affected by genotypes non-2/3 received 48 weeks of the treatment, while those affected by genotype 2 or 3 were treated 24 weeks.
Mecenate, 2010 / Subjects who were rapid viral responders at week 4 received Peginterferon alpha-2a 180 µg per week plus Ribavirin 1000-1200mg per day for 12 weeks in one arm, and for 24 weeks in the other arm. Subjects who were HCV RNA positive at week4 received Peginterferon alpha-2a 180 µg per week plus Ribavirin 1000-1200mg per day for 24 weeks.
Meyer-Wyss, 2006 / Subjects affected by genotypes 1 or other received 48 weeks of treatment, while those affected by genotype 2 or 3 were treated for 24 weeks.
Napoli, 2008 / Subjects received Peginterferon alpha-2b at a dose of 1.5μg/kg once a week for the first 4 weeks and achieved rapid viral response, and then received Peginterferon alpha-2b at a dose of 1.0µ g/kg once a week for the remaining 44 weeks.
Roberts, 2009 / In one arm subjects received Peginterferon alpha-2a 180 µg per week plus Ribavirin 1000-1200mg per day for 48 weeks, and in the other arm subjects received Peginterferon alpha-2a, 360μg per week, for the first 12 weeks and then 180μg per week for 36 weeks plus Ribavirin 1000-1200mg per day for 48weeks.
Rumi, 2010 / Subjects affected by genotypes 1 and 4 received 48 weeks of treatment, while those affected by genotype 2 or 3 were treated for 24 weeks.
Therapy was discontinued in HCV-1 and HCV-4 patients if quantitatve HCV-RNA testing at week 12 dropped by less than 2 log compared with baseline value and at week 24 if HCV-RNA was still detectable in those patients in whom HCV-RNA dropped more than 2 log at week 12.
Rustgi, 2009 / Subjects with a less than 2-log decrease in baseline HCV RNA at week 24 discontinued the study treatment. Subjects with undetectable HCV RNA or 2-log or more decrease from baseline in HCV RNA continued the treatment until week 48.
Tang, 2008 / In one arm beyond the first undetectable serum HCV-RNA at either week 4, 8, or 12, subjects continued the treatment for further 12 weeks. Median duration of treatment is 20 weeks (range, 12 to 24).
In another arm beyond the first undetectable serum HCV-RNA at either week 4, 8, or 12, subjects continued the treatment for further 24 weeks. Median duration of treatment is 32 weeks. (range 28 to 36)
In another arm beyond the first undetectable serum HCV-RNA at either week 4, 8, or 12, subjects continued the treatment for further 36 weeks. Median duration of treatment is 44 weeks. (range 12 to 48)
In another arm subjects who were HCV RNA positive at week12 continued the treatment for 48 weeks.
Toyoda, 2009 / Subjects who were rapid viral responders at week 4 continued the treatment for 8 weeks in one arm and for 24 weeks in the other arm. Subjects who were HCV RNA positive at week 4 continued the treatment for 24 weeks.
Yu, 2006 / Subjects received Ribavirin 1000-1200mg per day plus Peginterferon alpha-2b at a dose of 80 µg/week for body weight ≦60kg, 100 µg/week for body weight >60kg for 24 weeks in one arm and for 48 weeks in the other arm.
Zeuzem, 2005 / Subjects who were rapid responders at week 6 received Peginterferon alpha-2a 180 µg per week plus Ribavirin 1000-1200mg per day for 24 weeks.
Subjects who were null responders at week 6 received Ribavirin 1000-1200mg per day plus Peginterferon alpha-2a at a dose of 180μg per week for 6 weeks (week 1-6), then stopped for the next 6 weeks (week 7-12), and 360μg per week for the other 42 weeks (week 13-54).